Stock Track | Biogen Soars 5.13% Intraday on Strong Q4 Earnings Beat and Above-Expectations 2026 Profit Outlook

Stock Track

Feb 06

Biogen's stock surged 5.13% during intraday trading on Friday, as investors reacted positively to the company's latest financial results and future guidance.

The biotechnology firm reported fourth-quarter 2025 adjusted earnings per share of $1.99, significantly surpassing the consensus estimate of $1.59. Quarterly revenue reached $2.28 billion, also beating expectations of $2.20 billion. More importantly, Biogen provided 2026 adjusted EPS guidance of $15.25 to $16.25, which is above Wall Street's average estimate of $14.92.

The stronger-than-expected profit outlook is driven by several factors: continued cost-cutting measures under CEO Christopher Viehbacher, growing sales of newer drugs including the Alzheimer's treatment Leqembi (which saw Q4 sales of approximately $134 million, up 54% year-over-year), and disciplined expense management that is helping offset declining sales from the company's mature multiple sclerosis franchise.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127361352"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127361352\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127361352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127361352","market":"us","top_or_hot":-1,"title":"Stock Track | Biogen Soars 5.13% Intraday on Strong Q4 Earnings Beat and Above-Expectations 2026 Profit Outlook","media":"Stock Track","content":"<p>Biogen's stock surged 5.13% during intraday trading on Friday, as investors reacted positively to the company's latest financial results and future guidance.</p><p>The biotechnology firm reported fourth-quarter 2025 adjusted earnings per share of $1.99, significantly surpassing the consensus estimate of $1.59. Quarterly revenue reached $2.28 billion, also beating expectations of $2.20 billion. More importantly, Biogen provided 2026 adjusted EPS guidance of $15.25 to $16.25, which is above Wall Street's average estimate of $14.92.</p><p>The stronger-than-expected profit outlook is driven by several factors: continued cost-cutting measures under CEO Christopher Viehbacher, growing sales of newer drugs including the Alzheimer's treatment Leqembi (which saw Q4 sales of approximately $134 million, up 54% year-over-year), and disciplined expense management that is helping offset declining sales from the company's mature multiple sclerosis franchise.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Biogen Soars 5.13% Intraday on Strong Q4 Earnings Beat and Above-Expectations 2026 Profit Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Biogen Soars 5.13% Intraday on Strong Q4 Earnings Beat and Above-Expectations 2026 Profit Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen's stock surged 5.13% during intraday trading on Friday, as investors reacted positively to the company's latest financial results and future guidance.</p><p>The biotechnology firm reported fourth-quarter 2025 adjusted earnings per share of $1.99, significantly surpassing the consensus estimate of $1.59. Quarterly revenue reached $2.28 billion, also beating expectations of $2.20 billion. More importantly, Biogen provided 2026 adjusted EPS guidance of $15.25 to $16.25, which is above Wall Street's average estimate of $14.92.</p><p>The stronger-than-expected profit outlook is driven by several factors: continued cost-cutting measures under CEO Christopher Viehbacher, growing sales of newer drugs including the Alzheimer's treatment Leqembi (which saw Q4 sales of approximately $134 million, up 54% year-over-year), and disciplined expense management that is helping offset declining sales from the company's mature multiple sclerosis franchise.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"","article_id":"1127361352","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127361352","pubTimestamp":1770390038,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Biogen's stock surged 5.13% during intraday trading on Friday, as investors reacted positively to the company's latest financial results and future guidance.The biotechnology firm reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"个股赛道|百健盘中大涨5.13%，第四季度盈利强劲超预期2026年盈利前景","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"Biogen's stock surged 5.13% during intraday trading on Friday, as investors reacted positively to the company's latest financial results and future guidance.The biotechnology firm reported fourth-quarter 2025 adjusted earnings per share of $1.99, significantly surpassing the consensus estimate of $1.59. Quarterly revenue reached $2.28 billion, also beating expectations of $2.20 billion. More importantly, Biogen provided 2026 adjusted EPS guidance of $15.25 to $16.25, which is above Wall Street's average estimate of $14.92.The stronger-than-expected profit outlook is driven by several factors: continued cost-cutting measures under CEO Christopher Viehbacher, growing sales of newer drugs including the Alzheimer's treatment Leqembi (which saw Q4 sales of approximately $134 million, up 54% year-over-year), and disciplined expense management that is helping offset declining sales from the company's mature multiple sclerosis franchise.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}